<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/2DED15EE-AB45-4F2E-81E6-B9C473466BFF"><gtr:id>2DED15EE-AB45-4F2E-81E6-B9C473466BFF</gtr:id><gtr:name>ZMBH; University of Heidelberg</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:department>Sch of Pharmacy</gtr:department><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/2DED15EE-AB45-4F2E-81E6-B9C473466BFF"><gtr:id>2DED15EE-AB45-4F2E-81E6-B9C473466BFF</gtr:id><gtr:name>ZMBH; University of Heidelberg</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/7D6AD8C6-7B62-418C-8A3C-E9CE35D9B8CA"><gtr:id>7D6AD8C6-7B62-418C-8A3C-E9CE35D9B8CA</gtr:id><gtr:firstName>Lee</gtr:firstName><gtr:otherNames>David</gtr:otherNames><gtr:surname>Buttery</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/2B942523-3D3D-4AB1-8B1C-CDB0691C970C"><gtr:id>2B942523-3D3D-4AB1-8B1C-CDB0691C970C</gtr:id><gtr:firstName>Gerlof</gtr:firstName><gtr:otherNames>Sebastiaan</gtr:otherNames><gtr:surname>Winkler</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/877AF669-9449-4215-958D-89F3C2A38B87"><gtr:id>877AF669-9449-4215-958D-89F3C2A38B87</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:otherNames>Martin</gtr:otherNames><gtr:surname>Fischer</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G1100205"><gtr:id>2A8300BC-2198-4BD0-AD10-4F617A07E700</gtr:id><gtr:title>Deadenylase enzymes as potential novel drug targets in osteoporosis, bone disease, and repair</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1100205</gtr:grantReference><gtr:abstractText>In the UK, women over 45 years old spend more time in hospital due to osteoporosis than heart disease, diabetes or breast cancer. Common hip, wrist, and spinal bone fractures due to decreased bone density are a huge financial cost to the NHS and impact significantly on morbidity and the quality of life, in particular of women and the elderly. Although several options are available for the prevention and treatment of osteoporosis, currently available drugs are not always effective. Moreover, not all patients tolerate the available medications due to side-effects. 
If successful, our project is the first step towards novel drugs of the future that may be useful for the treatment of osteoporosis, bone disease and repair. These future drugs will have more desirable characteristics compared to current medications. They will be available as tablets, have fewer side-effects and enhance bone formation directly by stimulating bone-forming cells. The idea behind the selection of the enzyme target in bone-forming cells comes from genetically engineered mice with heavy bones and studying the relevant enzymes in great detail. We will search for drug-like molecules by screening a large collection of thousands of compounds using robots. In parallel, we will use high-performance computer clusters to screen a database with information of up to 1 million compounds using ?cheminformatics?. We will then optimise our hits using synthetic chemistry and test the activity of our compounds by looking at bone formation in cell culture dishes. If successful, our research will identify molecules that may represent candidates for future drug development.</gtr:abstractText><gtr:technicalSummary>In this proof of concept project, we shall explore the development of small-molecule inhibitors of deadenylase enzymes as a novel therapeutic approach for bone-related diseases, such as osteoporosis. We hypothesise that small-molecule inhibitors of deadenylase enzymes involved in mRNA degradation lead to increased osteoblast activity, will enhance bone density in osteoporotic bone, and promote the healing of bone fractures. The basis for this hypothesis is the observation that the CNOT7 deadenylase is a repressor of osteoblast cell activity as exemplified by the observation that CNOT7-null mice have increased bone density. Similar effects on bone are observed in mice lacking the Tob protein, which interacts with the CNOT7 gene product as a positive regulator. The CNOT7 protein is a poly(A) ribonuclease involved in cytoplasmic mRNA degradation that acts as a repressor of bone morphogenic protein-mediated signalling in osteoblasts. 
We aim to identify small-molecule deadenylase inhibitors using an interdisciplinary approach that brings together expertise in the biochemistry and cell biology of gene regulation, the biology of osteoblast cells and bone tissue, and screening capabilities and medicinal chemistry at the University of Nottingham. We shall use complementary approaches to maximise the potential of identifying small-molecule inhibitors. In addition to virtual ligand screening based on high-resolution crystal structures that are available in the public domain, we will develop and deploy a fluorescent deadenylase assay screen of an extensive, chemically diverse library of small drug-like molecules using robotics. Hit compounds will be verified and their selectivity determined using secondary biochemical and cell-based screens with a range of deadenylase enzymes. Hit-to-lead conversion medicinal chemistry will be carried out and lead compounds will be profiled extensively in terms of target and cell potency, selectivity, specificity, and pharmacological action, including the use of human and rodent osteoblast cells. If successful, this strategy will identify lead compounds that can modulate bone formation in cell-based models in a manner that suggests potential therapeutic use, and that may represent candidates for future drug development. Furthermore, such compounds will have much wider use as chemical probes in molecular and cellular medicine.</gtr:technicalSummary><gtr:fund><gtr:end>2014-03-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-12-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>434710</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>ZMBH; University of Heidelberg</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Collaboration Heidelberg</gtr:description><gtr:id>3FB824FA-86F7-4895-8BF4-99B72A1BA307</gtr:id><gtr:impact>N/A</gtr:impact><gtr:partnerContribution>Partners will carry out the bulk of the work. The effect of deadenylase inhibitors on trypanosome biology will be studied.</gtr:partnerContribution><gtr:piContribution>Provided unique compounds synthesised in the course of the grant for testing on Trypanosomes.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>University Online Press Release 2011</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>793561F6-B7EE-46F5-BA39-256362DB17E2</gtr:id><gtr:impact>A press release was written with the University's Media Relations Manager and approved by the funder. The piece was published on the home page of the University of Nottingham under the heading 'Latest news'. 
http://www.nottingham.ac.uk/news/pressreleases/2011/november/drug-hunters-rebuild-our-bones.aspx

The news item was also published on the home page of the School of Pharmacy, University of Nottingham.
http://www.nottingham.ac.uk/pharmacy/news/news2011/new-treatment-for-fragile-bones.aspx


While the press release was not picked up by (local) press, many members of the pubic have viewed the news items. No evaluation of page views was completed.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>85000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Studentship MRC DTP</gtr:description><gtr:end>2019-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>9C8A4A8E-26A2-4CBD-A577-5412F7C9DA1E</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Screening assay for the discovery and characterisation of small-molecule inhibitors of deadenyase enzymes</gtr:description><gtr:id>AB7D99FD-475C-4287-92DE-1C3B305D378F</gtr:id><gtr:impact>Publication
Discovery of novel activities of known chemical entities
Characterisation of new activities of novel and known chemical entities</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Screening Assay</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:url>http://nar.oxfordjournals.org/content/early/2013/10/28/nar.gkt972.full</gtr:url></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>DNA product (plasmid): Prokaryotic expression vector PQE80L containing a CNOT6L cDNA that is codon optimised for expression in Escherichia coli.</gtr:description><gtr:id>75F091DC-C93A-41FB-8D7C-7A906AB81961</gtr:id><gtr:impact>This plasmid made it possible to express and purify the Ccr4/CNOT6L protein, which is used to assess the selectivity of drug-like inhibitors of the Caf1/CNOT7 enzyme.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>pQE80L-CNOT6L</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We disclosed novel activities for five known chemical entities.</gtr:description><gtr:id>960B0B3A-42D5-4E15-8CF6-F191517751C4</gtr:id><gtr:impact>Proof-of-principle that deadenylase enzymes, which are potential targets in osteoporosis and bone repair, can be targeted by small-molecule inhibitors.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Novel activities for known chemical entities</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:url>https://www.ncbi.nlm.nih.gov/pubmed/24170810</gtr:url></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>A series of compounds were generated and characterised in terms of their inhibitory activity versus the human Caf1/CNOT7 and PARN enzymes.</gtr:description><gtr:id>83E173C3-82C7-4F04-B88C-DD050A016DAA</gtr:id><gtr:impact>These compounds received interest from a number of academic groups in Europe and the US. It resulted in the formal exchange of reagents with one group in Germany and possible future collaborations were discussed with the National Cancer Institute, USA.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>New reagents</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:url>https://www.ncbi.nlm.nih.gov/pubmed/26299350</gtr:url><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>DNA product (plasmid): Prokaryotic expression vector PQE80L containing a CNOT7 cDNA that is codon optimised for expression in Escherichia coli.</gtr:description><gtr:id>8F57EB9D-9B4C-4F22-8ED7-3A70D2675F33</gtr:id><gtr:impact>This plasmid made it possible to express and purify the Caf1/CNOT7 protein used in a biochemical screening assay to identify drug-like inhibitors of this enzyme.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>pQE80L-CNOT7</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BB2B8919-BE13-4988-AAAE-CDADAA5A543F"><gtr:id>BB2B8919-BE13-4988-AAAE-CDADAA5A543F</gtr:id><gtr:title>The enzyme activities of Caf1 and Ccr4 are both required for deadenylation by the human Ccr4-Not nuclease module.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0ed0d8dc21d91f5c1ebfc8e892072ced"><gtr:id>0ed0d8dc21d91f5c1ebfc8e892072ced</gtr:id><gtr:otherNames>Maryati M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/56E3CB05-22E2-4587-96BA-1C795692E492"><gtr:id>56E3CB05-22E2-4587-96BA-1C795692E492</gtr:id><gtr:title>A fluorescence-based assay suitable for quantitative analysis of deadenylase enzyme activity.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0ed0d8dc21d91f5c1ebfc8e892072ced"><gtr:id>0ed0d8dc21d91f5c1ebfc8e892072ced</gtr:id><gtr:otherNames>Maryati M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/74D7AAB2-C6CF-42BD-87D6-0FB4495F77D4"><gtr:id>74D7AAB2-C6CF-42BD-87D6-0FB4495F77D4</gtr:id><gtr:title>Discovery, synthesis and biochemical profiling of purine-2,6-dione derivatives as inhibitors of the human poly(A)-selective ribonuclease Caf1.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/699d581c73b971da8b678722d19a4add"><gtr:id>699d581c73b971da8b678722d19a4add</gtr:id><gtr:otherNames>Jadhav GP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0960-894X</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1100205</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>149FA87E-B8CD-4FFC-B515-EAD312BED03B</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Musculoskeletal</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>